ClinicalTrials.gg
CompletedNCT05015764Updated Apr 4, 2025

Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study

An interventional study of Fluid Management and Reprieve Cardiovascular System in Heart Failure, sponsored by Reprieve Cardiovascular, Inc. Completed at 1 site in Georgia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Reprieve Cardiovascular, Inc · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Apr 2021, registered Jul 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Heart Failure with a site in Georgia — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure · Georgia.

Enrollment
28th of 44
31 · median 50
Started
2021
with 4 others
No phase
25 of 46
15 open now
Registered
23rd of 46
by date
Lead sponsor
2 of 46
Reprieve Cardiovascular, Inc

Among the 46 studies in Heart Failure with a site in Georgia, this one is the 28th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2021, is one of 25 with no phase, and was the 23rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 46 studies in Heart Failure with a site in Georgia are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Heart Failure with a site in Georgia, or all of them as a file.
02

Study summary

Reprieve Cardiovascular System for the Treatment of Subjects with Acute Decompensated Heart Failure Mechanistic Study

Read the detailed description

The key objective of the trial was to provide an optimized decongestion treatment for subjects with acute decompensated heart failure and identify the critical parameters that could be incorporated into the design of the next generation of the Reprieve Cardiovascular System.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized with a diagnosis of heart failure
  2. Patients ≥ 18 years of age able to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Inability to place Foley catheter or IV catheter
  2. Hemodynamic instability
  3. Dyspnea due primarily to non-cardiac causes
  4. Acute infection with evidence of systemic involvement
  5. Inability to follow instructions or comply with follow-up procedures.
  6. Other concomitant disease or condition that investigator deems unsuitable for the study
  7. Enrollment in another interventional trial during the index hospitalization
  8. less than 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Reprieve Cardiovascular System

    Device: Reprieve Cardiovascular System

  • Active comparator
    Standard of Care

    Other: Fluid Management

Interventions

  • OtherFluid Management

    Removal of excess extracellular fluid using diuretics

  • DeviceReprieve Cardiovascular System

    System with Fluid Management Module

06

What researchers measure

Primary outcomes

  1. Fractional Excretion of Sodium measured during therapy

    Average fractional excretion of sodium across all patients measured during therapy

    Time frame: End of treatment, an average of 24 hours

  2. Device and Procedure related AEs and SAEs

    Rate of device and procedure related AEs and SAEs

    Time frame: Through study completion, an average of 90 days

07

Study locations

1 site
  • Israeli-Georgian Medical Research Clinic Helsicore
    Tbilisi, Georgia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in May 2022, 12 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 12 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Aug 20, 2021
StartActual
Apr 12, 2021
Primary completionActual
May 2, 2022
CompletionActual
May 2, 2022
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05015764
Lead sponsor
Reprieve Cardiovascular, Inc
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Apr 12, 2021
Primary completion
May 2, 2022
Completion
May 2, 2022
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion